Pacira BioSciences Inc PCRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
-
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
-
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Trading Information
- Previous Close Price
- $25.20
- Day Range
- $36.27–36.33
- 52-Week Range
- $18.82–36.33
- Bid/Ask
- $36.30 / $36.31
- Shares Outstanding
- 39.86M
- Market Cap
- $1.45B
- Volume/Avg
- 21M / 583,071
Key Statistics
- Price/Earnings (Normalized)
- 9.69
- Price/Sales
- 1.43
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 14.77%
Company Profile
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 829
- Website
- https://www.pacira.com
Valuation
|
Metric
|
PCRX
|
|---|---|
Price/Earnings (Normalized) | 9.69 |
Price/Book Value | 1.49 |
Price/Sales | 1.43 |
Price/Cash Flow | 5.81 |
Price/Earnings
PCRX
Financial Strength
|
Metric
|
PCRX
|
|---|---|
Quick Ratio | 3.14 |
Current Ratio | 5.04 |
Interest Coverage | 1.22 |
Quick Ratio
PCRX
Profitability
|
Metric
|
PCRX
|
|---|---|
Return on Assets (Normalized) | 8.41% |
Return on Equity (Normalized) | 15.73% |
Return on Invested Capital (Normalized) | 9.40% |
Return on Assets
PCRX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|b?%m!%Cf | LOCK|@rKl | $68B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|y%QGmjN | LOCK|>WzGz | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|^<HN?s | LOCK|!$c | $40B | |||
| Zoetis Inc Class A
ZTS
| LOCK|k@X^@dz | LOCK|?Mt | $30B | |||
| Viatris Inc
VTRS
| LOCK|>%%@Y$ | LOCK|dPd | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|P& | LOCK|rsS | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|%c$H>B | LOCK|F@ | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|V<%J!Q@ | LOCK|q@y | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|BgL<&d | LOCK|zP^t& | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|%<MtCD | LOCK|l$ | $2B |
United States